Foralumab (NI-0401; 0.6-250 μg; p.o.; daily, for 5 d) delays the rejection of B6Rag2/ skin grafted onto the humanized mice[1].
Foralumab (0.6-250 μg; p.o. and i.h.; daily, for 5 d) prevents skin xenograft rejection in mice with human immune systems[1].
Foralumab (1-15 μg; p.o.; daily, for 5 d) has good bioavailability of intragastric in humanized mice[1].
| Animal Model: | Humanized NOD/SCID IL-2γc/ mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] |
| Dosage: | 15 μg |
| Administration: | Oral administration; daily, for 5 days and weekly dosing |
| Result: | Showed robust protection against graft rejection and prolongs graft survival.
Reduced proliferation of CD8+ T cells and reduced release of TNF.
Increased the concentration of IL-10.
|
| Animal Model: | Humanized NOD/SCID IL-2γc/ mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] |
| Dosage: | 1, 5, 15, 50, and 250 μg (p.o.), 0.6 mg/kg (i.h.) |
| Administration: | Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing |
| Result: | Had tolerant to autologous skin grafts in humanized mice. |
| Animal Model: | Humanized NOD/SCID IL-2γc/ mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] |
| Dosage: | 0, 5, 10, and 15 μg |
| Administration: | Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing |
| Result: | Increased human Ig on the surface of CD4+ and CD8+ T cells.
Had free mAb in the serum of mice
|
